ReviewCureus2025
Assessing the Occurrence of Hypertension in Patients Receiving Calcitonin Gene-Related Peptide Monoclonal Antibodies for Episodic and Chronic Migraine: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcitonin gene-related peptide (CGRP) monoclonal antibodies have emerged as effective preventive treatments for episodic and chronic migraine, but concerns have been raised regarding their potential cardiovascular safety profile, particularly the risk of hypertension. This systematic review aimed to assess the occurrence of hypertension in patients receiving CGRP monoclonal antibodies for migraine prevention. A comprehensive search of PubMed, Embase, Scopus, and Cochrane Library was conducted for studies published between January 2015 and June 2025. Five studies met the inclusion criteria, encompassing 75,065 patients across randomized controlled trials, observational studies, and real-world cohort analyses. The evidence suggests a differential risk profile between CGRP receptor antagonists and ligand-targeting antibodies, with erenumab (receptor antagonist) demonstrating greater blood pressure increases compared to fremanezumab. In patients with baseline hypertension, anti-CGRP treatment was associated with a slight annual increase in antihypertensive medication requirements, while normotensive patients showed minimal blood pressure changes. Clinical trials reported low incidence rates of hypertension adverse events, though post-marketing surveillance identified 362 hypertension events in over 245,000 patient-years of exposure. The temporal pattern suggests cumulative rather than immediate effects, with a small proportion of normotensive patients requiring antihypertensive treatment after erenumab initiation. These findings indicate that while the overall risk of hypertension appears modest, clinically meaningful effects on blood pressure regulation may occur, particularly in patients with pre-existing hypertension. Regular cardiovascular monitoring is recommended for patients receiving CGRP monoclonal antibodies, especially those with baseline cardiovascular risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.